* If you want to update the article please login/register
Results: The EPO AA genotype has a strong risk association with DR patients compared to normal people, and AC genotype has a strong protective relationship with DR. The EPO A allele has a strong risk association with DR, and C allele has a strong protective link with DR. When comparing DR patients and DM patients, the EPO CC genotype has a strong protective relationship with DR; the EPO A allele has a significant risk association with DR; and C allele has a strong protective link to DR; and C allele has a strong protective link with DR. The EPO GT genotype has a strong protective relationship with DR patients and healthy people when compared to controls, and TT genotype has a significant risk association with DR. EPO genotype is a risk factor for DR in Chinese type 2 diabetic patients, particularly the high-risk PDR.
Source link: https://doi.org/10.1155/2022/6900660
Abstract Background In comparison to other pre-clinical studies, recent clinical trials have shown that high dose erythropoietin therapy after kidney transplantation does not improve short-term results and raises the risk of thrombotic events. Methods Eight female Dutch Landrace pigs were exposed to unilateral renal ischemia for 45 minutes with simultaneous cannulation of the ureter of the ischemic kidney. During the observation period of seven days, ARA290 increased glomerular filtration rate. Conclusions The increase in renal function following renal ischemia/reperfusion and reduced structural damage in this research by ARA290 warrants further investigation into clinical use.
Source link: https://doi.org/10.1186/1479-5876-11-9
The results revealed that rhEPO promoted EPC and ST2 by promoting the mitosis without affecting cell apoptosis. In addition, rhEPO encapsulated in PLGA scaffolds accelerated the bone formation in rats' calvaria bone defect model. We cultured EPC and ST2 under hypoxia since the center of bone disease was hypoxia in the hypoxia atmosphere. Therefore, EPO is a promising factor for future research, as HIF-1 was restricted or interfered at 6 h, but protein and mRNA levels decreased at 6 h, while protein expression of VEGF was reduced or inhibited from 6 h.
Source link: https://doi.org/10.1080/21691401.2019.1699827
Also, the large, prospective, placebo-controlled, double-blind, multi-center clinical trial u201cEPO in Burns, u201d, was launched to investigate the effects of EPO versus placebo therapy in severely injured patients. U201cEPO in Burns U201d was defined as the time elapsed until complete re-epithelialization of a defined split skin graft donor site, according to the principal endpoint of the 'u201d's. Compared to the time it took for research wounds to heal the three stages of wound healing, the verum and control groups were compared. For each re-epithelialization level, the Cox regression model was used to analyze interactions between the study drug and concomitant medications. Despite the study's medications, we found a reduced risk of wound healing for women in comparison to men in our study population.
Source link: https://doi.org/10.3389/fphar.2022.812888
An increased amount of the HIF-2u03b1 protein and significant reactivation of the HIF-2-u03b1 target gene erythropoietin gene expression in mice's livers, a finding consistent with the HIF-2u03b1 pathway in blood vessel vascularization. In 18-month-old LRRK2 knockout mice, the kidney EPO concentration was reduced to 20% of the normal range. Our results reveal a novel role for LRRK2 in regulating EPO expression, suggesting a potentially novel relationship between PD genes and hematopoiesis.
Source link: https://doi.org/10.1155/2016/7681259
Because more than half of NCEs are practically insoluble in water, poor solubility is the biggest issue involved in the formulation of new chemical entities. To predict drug polymer miscibility, In silico docking was carried out with a variety of polymers. Using the co-grinding and solvent evaporation techniques, the screened-out polymer was used to produce RoC's binary SD in a variety of ratios. RoC's increasing solubility may be useful in RoC's modulation of the dyslipidemia response. Our results showed an ameliorative role of RSE-2 in dyslipidemia and its associated disorders. In addition, RSE-2 demonstrated no evidence of cytotoxicity against human liver cell lines. This report, encouragingly, shows that SD of RoC can be produced by EPO with a high rate of dissolution and increased therapeutic response to the drug.
Source link: https://doi.org/10.3390/ph15040492
The recombinant human erythropoietin was isolated from a CHO cell line and used as a control to determine EpoL effects. In PC12 cells and rat hippocampal slices, neuroprotection tests were carried out. Cells were pretreated with EpoL or Epo for 1 h and exposed to oxidative agents and oxidative agents during 1u00c2 h; cell viability was assayed at the end of the experiment by the MTT technique. Cell cultures treated with oxidative agents and pretreated with EpoL demonstrated neuroprotective results of 30% at a concentration 10 times lower than that of Epo. Our findings show EpoL has a more potent neuroprotective profile against oxidative stress, aided by EpoR activation, so EpoL stands out as an important target to develop a potential biopharmaceutical to treat various central nervous system pathologies related to oxidative stress such as stroke or neurodegenerative diseases.
Source link: https://doi.org/10.1016/j.redox.2017.09.010
Abstract Background: We examined how EPO therapy of chronic anemia of advanced renal disease is now the only method of care we encountered, in the hopes that such therapy would slow renal function decline. When starting EPO at a weekly dose of 5000 u00b1 500 units once the hematocrit was below 30%, the mean creatinine was 5. 0 1. 8 mg/dL. U00b1 5/4 mmHg, and at month_0 it was 149/76 mmHg, with 145/73 mmHg. Before month_0, 12/18 patients were on an ACE-i or ARB before month_0, and 14/18 were on it after that. According to pre- and post-EPO 1/creatinine results, the mean rate of decline was -0. 0140 0. 0119 and 0. 0017 respectively. When implemented together with strict metabolic monitoring, the anemia of chronic renal disease with erythropoietin may reduce renal function decline, which can lead to a determinant decline in renal function.
Source link: https://doi.org/10.1186/1471-2369-4-3
Although electroacupuncture in cerebral ischemia has been used to promote functional recovery, the actual mechanism of its protective function is unclear. We investigated the effects of EA stimulation in GV20 and ST36 to see the changes in erythropoietin-mediated Janus family tyrosine kinases 2 signal transducers and promoters of the transcription 3 cell pathway. The EA effect on rats with cerebral ischemic reperfusion injury were determined by the protein and mRNA expression levels of EPO, the EPO receptor, p-JAK2, JAK2, p-STAT3, and STAT3.
Source link: https://doi.org/10.1155/2017/6027421
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions